Biotech News

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

PLUS THERAPEUTICS, Inc. (PSTV)PLUS THERAPEUTICS, Inc.2026-06-25 13:46 ESTEarnings

HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces financial results for the first

Open original release

Related news

PSTVPLUS THERAPEUTICS, Inc.2026-06-30 11:30 EST

Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics to Provide Business Update Call on June 30, 2026

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

PSTVPLUS THERAPEUTICS, Inc.2026-06-25 13:46 EST

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

View all latest news

PLUS THERAPEUTICS, Inc.

PLUS THERAPEUTICS is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

PSTVZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

PSTVZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

PSTVBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

PSTVGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

PSTVMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 4.17 USD
Market cap: 27.54M USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States